A Phase 2 Extension of Study GCS-100-CS-4003
Launched by LA JOLLA PHARMACEUTICAL COMPANY · Jan 7, 2015
Trial Information
Current as of July 23, 2025
Withdrawn
Keywords
ClinConnect Summary
Galectin-3 contributes to fibrosis, is elevated in patients with ESRD, and correlates with adverse outcomes (de Boer et. al., 2011, Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). Animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney (Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). GCS-100 is a galectin-3 antagonist that has been shown to reduce fibrosis pre-clinically. Based on the role of galectin-3 and fibrosis in kidney disease, the Sponsor believes G...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent
- • 2. Subject was enrolled in GCS-100-CS-4003.
- Exclusion Criteria:
- • 1. Subject experienced a Grade 3 or worse adverse event related to GCS-100 in clinical study GCS-100-CS-4003.
- • 2. Systolic blood pressure ≤90 mmHg and ≥160 mmHg and diastolic blood pressure ≤40 mmHg and ≥100 mmHg at screening
- 3. Subject has clinical laboratory values of:
- • Hemoglobin: ≤9 g/dL
- • Total bilirubin: \>1.5X the upper limit of normal (ULN)
- • ALT and/or AST: \>2.5X ULN
- • 4. Subject has a concomitant disease or condition, including laboratory abnormalities, which, in the opinion of the investigator, could interfere with the conduct of the study or put the subject at unacceptable risk.
- • 5. Subject who may require renal replacement therapy within the next 2 months, at the discretion of the investigator.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical firm dedicated to the development of innovative therapies for patients with severe and life-threatening diseases. With a focus on advancing novel treatments through rigorous clinical trials, the company leverages cutting-edge science and technology to address unmet medical needs in areas such as kidney diseases and autoimmune disorders. Committed to improving patient outcomes, La Jolla collaborates with healthcare professionals and research institutions to bring transformative therapies from the laboratory to the clinic, ensuring a patient-centered approach throughout the development process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
La Mesa, California, United States
Tempe, Arizona, United States
Asheville, North Carolina, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
George Tidmarsh, MD, PhD
Study Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials